Method for administering a phosphodiesterase 4 inhibitor
AssigneeSmithKline Beecham Corporation
InventorsRobert D. Murdoch, Theodore T. Torphy, Barry D. Zussman
Life of this patent
Estimating the term…
Abstract
This invention relates to a method for increasing the dose of a PDE4 inhibitor that can be administered at one time and be tolerated by the patient by reducing the absorption rate or the rate of rise in plasma concentration of the inhibitor.
Claims8
A method for increasing the dose or systemic exposure of a drug which inhibits PDE4 over that administered in a treatment at a single point in time by at least about 2-fold and reducing the severity of or eliminating or avoiding the occurrence of one or more side effects, the method comprising formulating a controlled-release preparation comprising said drug and at least one pharmaceutically acceptable excipient capable of forming a controlled release formulation which delays appearance in the plasma of detectable amounts of said drug and wherein the resulting rate of rise in plasma concentration of said drug is at least about 10% less than that of an immediate release formulation containing the same amount of drug administered by the same route and administering said formulation to a patient.
A method for reducing the severity of or eliminating or avoiding the occurrence of one or more side effects of a drug which inhibits PDE4, the method comprising administering the drug in a formulation and/or in a manner which results in a reduction in the of rate of rise in plasma concentration of said drug by at least about 10% less than that of an immediate release formulation containing the same amount of drug administered by the same route.
A method for reducing the severity of or eliminating or avoiding the occurrence of one or more side effects of a drug which inhibits PDE4, the method comprising administering the drug in a formulation and/or in a manner which results in a delay in the appearance in the plasma of detectable amounts of said drug and results in a reduction of rate of rise in plasma concentration of said drug by at least about 10%, as compared with than that of an immediate release formulation containing the same amount of drug administered by the same route.
Dependencies are inferred from the claim text.